By Colin KellaherPfizer Inc. on Friday said it won U.S. Food and Drug Administration of its Zavzpret nasal spray for the acute treatment of migraine with or without aura in adults. The New York drugmaker said Zavzpret is the first and only calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine in adults and expands its migraine portfolio, which includes the blockbuster Nurtec ODT franchise.

Source: Wall Street Journal March 10, 2023 12:18 UTC